Pancreatic Risks No Greater with Liraglutide

The treatment of type 2 diabetes with liraglutide didn’t lead to a greater rate of acute pancreatitis or pancreatic cancer compared with other anti-diabetic drugs in an interim analysis. The incidence rate for acute pancreatitis among patients receiving the GLP-1 analog was 187.5 per 100,000 person-years compared with 154.4 per 100,000 for a group of pooled comparator drugs. The incidence rate for pancreatic cancer was 19.9 per 100,000 compared with 33 per 100,000 for the pooled comparator group. Diabetes, Obesity and Metabolism, Dec., 2013.